Clinical trials: Difficile
Inflammatory Bowel Diseases, Clostridium Infections
Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
In recent years, the incidence of Inflammatory Bowel Disease (IBD) has been increasing in China, which poses great challenges and burdens to the medical community due to its unknown etiology, recurrence and incurability.
- Trial name
- NCT04179201
- Where
- 6 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Clostridium Difficile Infection
Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum
Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C.
- Trial name
- NCT01914731
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Clostridioides Difficile Infection
Study of Clostridioides Difficile in Infants
Clostridioides difficile infection (CDI) poses an increasing threat to infant and young child health, with detection rates rising annually.
- Trial name
- NCT06788769
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Westlake University
Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile
Animal-Assisted Visitation Program Chlorhexidine Trial
Hospital-based Animal-Assisted visitation programs are important complementary therapies, but concerns with infection control may challenge the sustainability of these programs.
- Conditions
- Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
- Trial name
- NCT04171817
- Testing
- Chlorhexidine
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Multidrug Resistant Organisms, Healthcare Associated Infections
Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)
Enhanced terminal room disinfection is a novel, promising, but still unproven strategy for the prevention of healthcare-associated infections (HAIs) due to selected multidrug-resistant (MDR) bacterial pathogens.
- Trial name
- NCT01579370
- Testing
- Quaternary ammonium, Bleach, Quaternary ammonium and UV-C light
- Where
- 9 sites in United States
- Volunteers
- 21,395 people
- Sponsor
- Duke University
Cross Infection, Clostridium Difficile Infection
Evaluation of the Cost of a Nosocomial Infection With Clostridium Difficile
Clostridium difficile is the first cause of nosocomial infectious diarrhea, due to its mode of transmission and its resistance in the environment.
- Trial name
- NCT03025672
- Volunteers
- 10,445 people
- Sponsor
- Lille Catholic University
Clostridium Difficile Infection
Fecal Microbiota Transplant by Oral Capsules With Lactobacilli for Recurrent Clostridium Difficile Infection
Investigators designed an open, two-arm study to compare fecal microbiota transplant by oral capsules (FMT-c ) versus FMT-c enriched with Lactobacillus for treatment of C. difficile recurrent infection
- Trial name
- NCT03804736
- Testing
- FMT-c, FMT-c Lactobacillus
- Volunteers
- 21 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Clostridium Difficile Infection
Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection
Acquiring diarrhoea in hospital is a serious problem and most frequently occurs when susceptible patients receive antibiotics as part of their (often life-saving) care.
- Trial name
- NCT02086916
- Where
- United Kingdom
- Volunteers
- 122 people
- Sponsor
- Barts & The London NHS Trust
Clostridium Difficile Infection
Protocol for Admission Toxigenic C. Difficile Surveillance
Background: Clostridioides (formerly Clostridium) difficile Infection (CDI) is a persistent healthcare issue. In the US, CDI is the most common infectious cause of hospital-onset (HO) diarrhea.
- Trial name
- NCT04014608
- Testing
- Standard Practice to Prevent Hospital Onset CDI
- Where
- United States
- Volunteers
- 148,549 people
- Sponsor
- Endeavor Health
Clostridium Difficile Infection
Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries
The aim of this study is to conduct an Asia-Pacific, multi-center, prospective observational study to characterize patients with CDI as well as to understand treatment and management of the disease.
- Trial name
- NCT02223715
- Testing
- CDI Pts
- Where
- Japan
- Volunteers
- 600 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Clostridium Difficile Infection
Study on Clostridium Difficile Infection in Infants
This study aims to investigate the epidemiological characteristics and biomarkers of Clostridium difficile infection in infants .
- Trial name
- NCT06703918
- Where
- China
- Volunteers
- 150 people
- Sponsor
- First People's Hospital of Hangzhou
C. Difficile Infection
Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy
The investigators found that community acquired C. diff occurs in children undergoing a colonoscopy. When they were treated their symptoms got better. But, the investigators do not know if the treatment for the C.
- Trial name
- c diff (NCT01472978)
- Testing
- metronidazole
- Where
- United States
- Sponsor
- State University of New York at Buffalo
Clostridioides Difficile Infection
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
- Trial name
- Ri-CoDIFy 3 (NCT04802837)
- Testing
- Ridinilazole, Vancomycin
- Where
- 18 sites in United States
- Volunteers
- 2 people
- Sponsor
- Summit Therapeutics
Fecal Microbiota Transplantation, Clostridium Difficile Infection
Fecal Microbiota Transplant National Registry
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
- Conditions
- Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
- Trial name
- FMT (NCT03325855)
- Testing
- None - Observational
- Where
- 53 sites in United States, Canada
- Volunteers
- 4,000 people
- Sponsor
- American Gastroenterological Association
Bacteria Infection Mechanism
Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Difficile in Infants
Clostridioides difficile (formerly C. difficile) is a bacterium found in the form of spores (a resistant form) to which patients may be exposed in a hospital environment.
- Trial name
- BBDIFF (NCT07512908)
- Testing
- cohort follow up
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Clostridium Difficile
Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections
Background: There is an urgent need to develop new strategies to prevent Clostridium difficile infections (CDI). A recent study suggests that a novel infection control bundle (IC bundle) can lead to a significant decrease in the…
- Trial name
- EFFICACI (NCT03223415)
- Testing
- Detection and isolation of C. difficile carriers
- Where
- 5 sites in Canada
- Volunteers
- 4,138 people, healthy volunteers welcome
- Sponsor
- Yves Longtin
Clostridium Difficile Infection
COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium difficile infection (CDI) is the most common cause of antibiotic associated diarrhoea in the western world. The infection causes significant diarrhoea, which in some cases can be serious and lead to secondary…
- Trial name
- COMBACTE-CDI (NCT03503474)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 3,240 people
- Sponsor
- University of Leeds
Ulcerative Colitis
Role of Bile Acids and Microbiota in Clostridioides Difficile Infection in Ulcerative Colitis
Ulcerative Colitis (UC) is a chronic Inflammatory Bowel Disease characterized by chronic inflammation of the colon. Composition of gut microbiota of UC patients is abnormal (dysbiosis).
- Trial name
- ABRICO (NCT06228352)
- Testing
- Feces collection
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mediterranean Fever, Colchicine Resistance
Study of Colchicine Resistance in Familial Mediterranean Fever
Five to 10% of familial mediterranean patients are considered colchicine-resistant (i.e. patients with a persistent inflammatory syndrome, despite taking the maximum tolerated dose of colchicine daily).
- Trial name
- COLCHI-RESIST (NCT05418686)
- Testing
- Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Recurrent Clostridium Difficile Infection, Multidrug-resistant Klebsiella Pneumoniae Urinary Tract Infection
Fecal Microbiota Transplantation (FMT): PRIM-DJ2727
The Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727 is prepared from human stool from a healthy, screened donor. Requestors will contact the study team about the product (PRIM-DJ2727) by email, visit, or phone call.
- Trial name
- NCT03786900
- Testing
- Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727
- Sponsor
- Herbert DuPont, MD